Drugs / mRNA HBV/TCR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04745403 | May 2022 → Jul 2026 overdue | hepatocellular carcinoma | Lion TCR Pte. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA HBV/TCR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04745403 ↗ |
| Action | Deplete | “HBV-specific T cells lysed HBV-producing hepatoma cells in vitro.” PMID 28737510 ↗ Jul 2017 |
| Modality | Cell therapy | “To develop a more practical and safer approach to cell therapy of HCC, we used electroporation of mRNA encoding anti-HBV TCR.” PMID 23941866 ↗ Aug 2013 |